1 2

10A NCAC 26F .0106 is amended without notice or hearing pursuant to G.S. 90-88(d) as follows:

3 10A NCAC 26F .0106 SCHEDULE V

4 (a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name,

5 chemical name or brand name designated and listed in either G.S. 90-93 or this Rule. Each drug or substance is set

6 forth below with its corresponding Drug Enforcement Administration (DEA) controlled substances code number set

7 forth in the Code of Federal Regulations, Title 21, Section 1308.15.

8 (b) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation

9 containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in

10 limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in

sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than

12 those possessed by narcotic drugs alone:

13 (1) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams,

14 (2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams,

15 (3) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams,

16 (4) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate
 17 per dosage unit,

18 (5) not more than 100 milligrams of opium per 100 milliliters or per 100 grams,

19(6)not more than 0.5 milligrams of difenoxin and not less than 25 micrograms atropine sulfate per20dosage unit.

(c) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material,
 compound, mixture, or preparation which contains any quantity of the following substances having a stimulant
 effect on the central nervous system, including its salts, isomers and salts of isomers: Pyrovalerone - DEA controlled
 substances code number 1485.

(d) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material,
 compound, mixture, or preparation which contains any quantity of the following substances having a depressant
 effect on the central nervous system, including its salts:

28

29

(1) Lacosamide – DEA controlled substances code number 2746; and

(2) Ezogabine – DEA controlled substances number 2779.

30 (e) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the U.S.

31 Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R (1-methylethenyl) 2 cyclohexen 1-

32 yl] 5 pentyl 1,3 benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual

33 tetrahydrocannabinols DEA controlled substances code number 7367.

34

36

35 History Note: Authority G.S. 90-88; 90-93; 143B-147;

Eff. June 30, 1978;

37 Amended Eff. July 1, 2012; February 1, 2010; April 1, 1992; August 1, 1988; December 1, 1987;
38 April 1, 1983;
39 Pursuant to G.S. 150B-21.3A, rule is necessary without substantive public interest Eff. February
40 2, 2016;
41 Amended Eff. <u>March 1, 2021</u>; January 1, 2019.